NeuroKinetic Medical stops Stage I & II pressure injuries before they progress — using proprietary electrical stimulation and an AI-driven platform across hospital, long-term care, and home settings.
Navigate to any section to learn more about who we are, why this moment matters, what Prelivia does, and how it's proven.
Whether you’re a clinician, health system leader, or investor — we’d like to talk.
Founded on 15+ years of electrical stimulation science, cleared by the FDA and Health Canada, and now executing on US commercial launch.
NeuroKinetic Medical is a medtech company transforming outcomes for patients at risk of pressure injuries — a costly, largely preventable clinical burden affecting millions of patients annually across hospital, long-term care, and home health settings.
Our flagship platform, Prelivia™, targets Stage I and Stage II pressure wounds — the 98.7% of pressure injuries that are still reversible — before they progress to the costly, unreimbursed Stage III and IV events that devastate patients and health system finances alike.
Built on 15+ years of electrical stimulation IP through our acquisition of Rehabtronics Inc., and cleared by the FDA and Health Canada, we are now executing on US commercial launch while advancing the next generation of the platform. Phase 1 is pressure injury prevention — the same platform applies to diabetic ulcers, venous ulcers, and beyond.
Explore our clinical evidence, platform features, or reach out directly.
Four forces have aligned to make NeuroKinetic not just possible, but necessary — today. Each one is a tailwind. Together, they create an extraordinary window.
Edge technology and AI inference is now part of hospital infrastructure, creating the sensor-enabled environment that NeuroKinetic leverages to deliver real-time, adaptive, individualized intervention at the bedside. The infrastructure cost NeuroKinetic nothing to build — it already exists in hospitals and nursing homes today.
CMS penalties and litigation costs now make pressure injuries a P&L line item, not just a QA metric. New regulations extend penalties to Stage II injuries. The average nursing home pressure ulcer lawsuit pays out $500K+. A mid-size hospital in the worst HACRP quartile loses $3M+ per year in Medicare revenue alone.
Every pressure injury case costs hospitals $40,000+ in additional care and extends stays by 4+ days — with zero CMS reimbursement. Medicare insolvency is projected within 7 years. Hospitals and nursing homes face spiraling costs, and pressure injury prevention is one of the highest-yield cost reduction interventions available to them right now.
Nurse-to-patient ratios are at historic lows. A 160-bed hospital needs 10 nurses working 24/7 just for pressure injury management under current protocols — 100+ nursing hours per day for patient turning alone. With Prelivia, the same preventive outcome requires approximately 10 minutes of nursing time per patient per session.
Platform features built to solve every one of these problems directly.
A bedside durable unit plus consumable proprietary pads plus an AI protocol engine — FDA 510(k) cleared and deployable in hospital, long-term care, and home settings with minimal nursing burden.
Prelivia targets the 98.7% of pressure injuries that are still reversible — before they advance to Stage III and IV. It works in every setting, with every patient population, with 100% patient acceptance in all clinical trials.
Stops Stage I/II wounds from progressing to costly unreimbursed Stage III/IV events. Targets sacrum & buttocks — 59% of all pressure wound sites — with the current form factor.
Machine learning continuously refines stimulation parameters based on real-time tissue response. Each session is individualized — no two patients receive identical treatment. 250 nurses trained to date.
Epic App Orchard listing in roadmap. Connects with hospital EHR systems, automating documentation and enabling outcome tracking. Partial integrations active today.
Designed for hospital, long-term care, and home healthcare. Minimal setup and low cognitive load. Clinician-designed interface co-developed with wound care nurses and physicians.
Roadmap includes diabetic ulcers and venous ulcers — significantly expanding the addressable market. Phase 1 is pressure injury prevention; the platform is built for much more.
412-patient RCT generates labeled training data competitors lack. Federated learning improves the model without sharing PHI. Core algorithm embedded in a secure hardware enclave. Each deployment makes Prelivia smarter.
One-time device placement generates continuous high-margin consumables revenue with deep lock-in and 3–5 year enterprise contract terms.
Low-cost install per bed. One-time placement creates the foundation for ongoing consumables revenue.
Changed every 24–72 hours per patient. ~68% gross margin. No substitution possible — pure recurring revenue.
Enterprise contracts on 3–5 year terms. EHR integration, outcomes analytics, and clinical support included. High switching costs.
De-identified outcomes dataset. Pharma & device partners. Outcomes-based contracts via % of documented HAPI savings.
Our clinical team will walk you through the platform, share outcomes data for your patient population, and support your evaluation process.
A rigorous, peer-reviewed evidence base supporting the safety and efficacy of Prelivia — from pre-clinical studies through a 412-patient prospective RCT across 3 Magnet-designated hospital systems.
Animal & human studies completed. 68 patients across ICU, Acute & LTAC settings. Published in Annals of Biomedical Engineering and Journal of Applied Physiology. 28% increase in tissue oxygenation. 80% reduction in tissue damage.
Randomized controlled trial across 3 Magnet-designated hospital systems. 87% HAPI reduction, Stage II+. 91% sensitivity at 18 hours. Zero pressure injuries in treated patients across all completed trial arms. 100% patient acceptance.
Core science peer-reviewed and replicated. RCT submitted to WOUND journal — peer review in progress. IRB approved. NCT registered.
Per 300-bed hospital deployment — first-year analysis
Full clinical dossier, peer-to-peer investigator discussions, or facility evaluation support — we’re ready.
Competition is fragmented, reactive, and single-point. NeuroKinetic is the only end-to-end AI platform for pressure injury prevention and management — with a compounding moat of IP, data, regulatory trust, and clinical relationships.
Regulatory clearance from the FDA and Health Canada removes the single largest risk factor for medtech investors and health system procurement. Prelivia is cleared, ISO certified, and generating revenue in both the US and Canada now.
Prelivia detects and intervenes at the sub-surface tissue level before visible skin breakdown. This is the 98.7% window where intervention is still reversible. Bruin Biometrics detects sub-surface injury; no one else both detects and treats it end-to-end.
8 patents issued, 2 pending. A proprietary 18-month training dataset from the RCT. Federated learning improves the model without sharing PHI. Core algorithm embedded in a secure hardware enclave. Each deployment compounds the advantage.
The only platform offering outcomes-based contracts tied to documented HAPI cost savings. This aligns NeuroKinetic’s economics with health system performance, creating durable enterprise relationships and positioning well for ACO and value-based care contracts.
| Capability | NeuroKinetic | Bruin Biometrics | Leaf Healthcare | Stryker Smart Bed | Traditional Care |
|---|---|---|---|---|---|
| Sub-surface predictive detection | ✓ | ✓ | — | — | — |
| End-to-end management tools | ✓ | — | — | — | — |
| EHR integration | ✓ | Partial | — | Partial | — |
| Outcomes-based pricing | ✓ | — | — | — | N/A |
| Positive patient experience | ✓ | — | ✓ | ✓ | Manual |
| FDA clearance | 510(k) | 510(k) | None req. | None req. | N/A |
87% HAPI reduction. 4.1× ROI. 5 peer-reviewed publications. The data backs every claim.
Clinical depth + commercial execution + technology leadership — the three capabilities that matter most in medtech commercialization, united in one founding team.
We’re building a category-defining company. Reach out to discuss clinical collaborations, commercial partnerships, or career opportunities.
Paid pilots, strategic industry relationships, and regulatory clearances across three jurisdictions — traction that validates both clinical efficacy and commercial readiness.
Whether you’re a health system, device company, distributor, or research institution — we’d like to hear from you.
Whether you’re a clinician, investor, health system leader, or strategic partner — we’d like to hear from you.